2003
DOI: 10.1002/ccd.10620
|View full text |Cite
|
Sign up to set email alerts
|

Society of cardiac angiography and interventions: Suggested management of the no‐reflow phenomenon in the cardiac catheterization laboratory

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
58
1

Year Published

2004
2004
2016
2016

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 54 publications
(59 citation statements)
references
References 60 publications
0
58
1
Order By: Relevance
“…These high-risk patients should therefore be identified because they may benefit from adjunctive intracoronary therapies such as adenosine, verapamil, or nitroprusside. 24 …”
Section: Discussionmentioning
confidence: 99%
“…These high-risk patients should therefore be identified because they may benefit from adjunctive intracoronary therapies such as adenosine, verapamil, or nitroprusside. 24 …”
Section: Discussionmentioning
confidence: 99%
“…Vol 48 No 1 plaque in the lesions with slow flow and a side branch compromised after PCI were significantly lower compared to those in the lesions without the complication of PCI, and the CT density of plaque in the lesions with dissection and perforation after PCI was the highest (25.1 ± 41.8 HU, 257.1 ± 377.8 HU, and 712.1 ± 180.7 HU, P < 0.05).…”
mentioning
confidence: 87%
“…Despite its numerous benefits, serious and potentially life-threatening complications of PCI can occur, including slow flow phenomenon, 1,2) and coronary dissection and perforation. 3,4) PCI, which depends upon mechanical dilatation of the artery or ablation of atherosclerotic plaque, is requisitely associated with plaque rupture, 5,6) plaque fracture, intimal splitting, localized media dissection, and frank perforation.…”
mentioning
confidence: 99%
“…Drug treatment aimed at reducing the no-reflow phenomenon may improve myocardial salvage, thus preventing left ventricular remodeling [2,3,4,5,6]. Various treatment strategies have been associated with an improvement in angiographic flow in several studies, but whether these treatment strategies affect clinical outcome is not clear [2,3,4,6].…”
Section: Introductionmentioning
confidence: 99%
“…Diagnostic techniques to measure tissue perfusion have validated this concept in humans and it is now clear that abnormal tissue perfusion occurs frequently in STEMI patients undergoing primary percutaneous coronary intervention (PCI). The presence of no-reflow during PCI has been associated with worsened short- and long-term outcomes, the risk of subsequent major adverse events and negative remodeling [1,2,3,4,5,6,7]. …”
Section: Introductionmentioning
confidence: 99%